Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-Current Assets (2016 - 2026)

Anika Therapeutics has reported Non-Current Assets over the past 17 years, most recently at $85.8 million for Q1 2026.

  • Quarterly Non-Current Assets fell 2.58% to $85.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $349.0 million through Mar 2026, down 8.2% year-over-year, with the annual reading at $86.9 million for FY2025, 2.44% down from the prior year.
  • Non-Current Assets was $85.8 million for Q1 2026 at Anika Therapeutics, down from $86.9 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $186.3 million in Q2 2022 and troughed at $85.8 million in Q1 2026.
  • The 5-year median for Non-Current Assets is $107.3 million (2023), against an average of $128.9 million.
  • Year-over-year, Non-Current Assets grew 1.03% in 2023 and then tumbled 44.39% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $179.6 million in 2022, then plummeted by 40.24% to $107.3 million in 2023, then decreased by 16.99% to $89.1 million in 2024, then dropped by 2.44% to $86.9 million in 2025, then dropped by 1.25% to $85.8 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Non-Current Assets are $85.8 million (Q1 2026), $86.9 million (Q4 2025), and $87.8 million (Q3 2025).